CardioRenal has developed the first in the world connected self-test allowing Heart Failure or Kidney disease patients to monitor their blood potassium at home as easily as diabetic patients measure their glycemia. The device, TENOR, has been validated in a clinical study in Brussels. TENOR, is currently going through CE clinical trial and has been granted « breakthrough device label » by FDA. Commercialisation in Europe will start in 2024.
December 3rd & 4th, 2024